JBJu Young Bae

Ju Young Bae

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ju Young Bae has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Physiologic Assessment of Coronary Artery Disease: A Practical Guide

    by Ju Young Bae, Alexa Distaso, Sara Pollanen, Suhail Dohad, Jiun-Ruey Hu, S. Elissa Altin

  • Open Access

    Coronary Bifurcation PCI—Part II: Advanced Considerations

    by Rongras Damrongwatanasuk, Sara Pollanen, Ju Young Bae, Jason Wen, Michael G. Nanna, Abdulla A. Damluji, Mamas A Mamas, Elias B. Hanna, Jiun-Ruey Hu

    Performance of percutaneous coronary intervention (PCI) for bifurcation lesions involves complex decision-making informed by anatomic, hemodynamic, technical, and clinical factors. Building on the procedural foundations discussed in the companion paper in this two-part series, this second paper focuses on advanced considerations in bifurcation PCI. Factors associated with side branch (SB) compromise are discussed, including bifurcation angle and distribution of plaque location, along with strategies for SB protection and SB rewiring. Outcomes of landmark randomized controlled trials of provisional versus two-stent approaches, as well as specific two-stent techniques, are summarized. Based on these factors, an algorithmic approach for bifurcation PCI is outlined. Lastly, the use of drug-coated balloons, dedicated bifurcation stents, bioresorbable vascular scaffolds, bioadaptor stents, physiologic testing, intravascular imaging, and other emerging innovations are explored to provide a perspective on the future of bifurcation PCI.


  • Open Access

    Coronary Bifurcation PCI—Part I: Fundamentals

    by Sara Pollanen, Rongras Damrongwatanasuk, Ju Young Bae, Jason Wen, Michael G. Nanna, Abdulla Al-Damluji, Mamas A. Mamas, Elias B. Hanna, Jiun-Ruey Hu

    Percutaneous coronary intervention (PCI) of bifurcation lesions remain one of the most technically challenging areas in interventional cardiology. Careful planning and execution are needed to preserve main vessel and side branch patency, with evolving evidence guiding the choice between provisional and two-stent strategies, and between individual techniques. This narrative review, which represents the first installment of a two-part series, synthesizes current knowledge on bifurcation PCI, detailing the anatomical classifications, lesion assessment tools, procedural planning, and execution of techniques including T and Protrusion (TAP), double-kissing (DK) crush, mini-crush, culotte, V-stent, and emerging modifications. We contextualize the choice of strategy within lesion complexity, procedural goals, and patient-specific considerations. This review is intended as a visual, practical, technique-focused reference for interventionalists and interventional trainees involved in the management of bifurcation lesions.


  • Open Access

    In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy

    by Ju Young Bae, Dae Yong Park, Soumya Banna, Jiun-Ruey Hu, Amr Saleh, Mamas A. Mamas, Robert L. McNamara, Michael G. Nanna, John F. Setaro, Luke K. Kim, et al.

    Background: Despite the high prevalence of malignant pericardial effusions (MPEs), the differences in mortality between those undergoing pericardiocentesis for MPE versus non-malignancy pericardial effusions (NMPEs) are not well characterized. To address this knowledge gap, we aim to compare clinical outcomes following pericardiocentesis among patients with MPE and NMPE. Methods: A retrospective analysis was conducted on the US National Inpatient Sample (NIS) to identify all hospitalizations during which pericardiocentesis was performed between 1 January 2016 and 31 December 2020 (total n = 174,776,205). This cohort was further stratified based on the presence or absence of malignancy. The primary outcome of interest was in-hospital mortality. Secondary outcomes included discharge disposition (categorized as non-home discharges), length of stay, and total hospitalization costs. Results: A total of 85,125 patients with pericardial effusions undergoing pericardiocentesis were identified. Patients with an MPE (n = 24,740) were younger and more likely to have a history of malnutrition, prior radiation, palliative care treatments, and do-not-resuscitate (DNR) orders compared to those with an NMPE (n = 60,385). Lung cancer was the most common malignancy (40.3%) in patients with an MPE requiring pericardiocentesis. The in-hospital mortality following pericardiocentesis was 11.8% in patients with malignancy and 8.2% in patients without (odds ratio (OR) for mortality 1.50 (95% confidence interval [CI]: 1.34–1.68, p < 0.001). Lung cancer, non-Hodgkin lymphoma, esophageal cancer, ovarian cancer, and leukemia were associated with a significantly increased risk of death during the same admission. Non-home discharge, length of stay, and total hospitalization cost were marginally greater in those with an MPE. Conclusions: In patients undergoing pericardiocentesis, those with an MPE had significantly higher in-hospital mortality compared to those with an NMPE. Additionally, the MPE group had a marginally longer length of stay and incurred higher total hospital costs. Further research is warranted to explore optimal treatment strategies for MPEs, particularly in patients with a limited life expectancy.


  • Open Access

    Early Clinical Outcomes of Patients With Stress-Induced Cardiomyopathy Receiving Acute Mechanical Support in the US

    by Sun-Joo Jang, Fabricio Malaguez Webber, Mashiul Alam, Ju Young Bae, Abhinav Aggarwal, Alexander Thomas, Stuart W. Zarich, Tariq Ahmad, P. Elliott Miller, Carlos D. Davila


  • A call to consider an aortic stenosis screening program

    by Ju Young Bae, Arzhang Fallahi, Wayne Miller, Martin B. Leon, Theodore P. Abraham, Sripal Bangalore, David H. Hsi


  • Open Access

    Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia

    by Ryan L. Kelly, Ju Young Bae, Samantha D\'ANnunzio, Francesca Montanari

    Unknown etiology Chronic myeloid leukemia (CML) is a myeloproliferative malignancy generally treated with Dasatinib, a tyrosinkinase inhibitor. Pleural effusions are a known adverse effect, but only 0.8% of patients develop pleural effusions after 6 years of use. Recent case reports have implicated Dasatinib as a rare cause of chylothorax. We describe a woman in her 30’s with a history of chronic myeloid leukemia, who had been taking Dasatinib for 10 years and presented to the Emergency Department after a chest X-ray revealed bilateral pleural effusions in the setting of worsening dyspnea on exertion for 6 months. She had previously received radiotherapy at age 11 prior to an allogenic bone marrow transplant nearly 30 years prior. Thoracentesis removed 900 cc of chylous fluid, and flow cytometry and cultures found no evidence of infection or malignancy. Dasatinib was discontinued, and she was treated with diuretics, steroids, and a low-fat diet. The effusions reaccumulated twice in the following month and required 2 additional thoracenteses and courses of steroids. Months later, the bilateral chylous effusions recurred, and MR lymphangiogram demonstrated 2 thoracic duct tears. While previous reports have indicated that Dasatinib can rarely cause chylous pleural effusions, it is unlikely after 5 years of use, and other etiologies must be considered by clinicians. Initial misattribution to Dasatinib alone can delay further necessary investigations, including lymphangiography. In our patient, it is more likely that other factors contributed to her chylothorax, including her previous radiotherapy 30 years prior, given her recurrence of chylous effusions following cessation of the medication.


  • Open Access

    Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression

    by Hyunsuk Kim, Jinmo Sung, Ju Young Bae, Poongyeon Lee, Yun Kyu Oh, Hyunho Kim

    Background: Autosomal dominant polycystic kidney disease (ADPKD), one of the most common human monogenic diseases, is characterized by the presence of numerous fluid-filled renal cysts and is a leading cause of end-stage renal disease (ESRD). Urinary biomarkers may be useful for predicting the variable course of ADPKD progression from cyst growth to ESRD.Methods: To identify candidate urinary biomarkers of ADPKD progression, we used CRISPR/Cas9 genome editing to generate porcine fibroblasts with mono- and biallelic ADPKD gene knockout (PKD2+/ and PKD2/, respectively). We then performed RNA-sequencing analysis on these cells.Results: Levels of osteopontin (OPN), which is expressed by renal epithelial tubular cells and excreted into urine, were reduced in PKD2/ cells but not in PKD2+/ cells. OPN levels were also reduced in the renal cyst cells of ADPKD patients. Next, we investigated whether OPN excretion was decreased in patients with ADPKD via enzyme-linked immunosorbent assay. OPN levels excreted into renal cyst cell culture media and urine from ADPKD patients were decreased. To investigate whether OPN can predict the rate of ADPKD progression, we compared urinary excretion of OPN in ADPKD patients with slow progression and those with rapid progression. Those with rapid progression had an estimated glomerular filtration rate of >60 mL/min/1.73 m2. Urinary OPN excretion levels were lower in rapid progressors than in slow progressors.Conclusion: These findings suggest that OPN is a useful urinary biomarker for predicting ADPKD progression.


  • Open Access

    Direct current cardioversion-triggered atypical Tako-tsubo cardiomyopathy: a case report and review of literature

    by Ju Young Bae, Joseph Tartaglia, Michael Chen, John F Setaro

    Background: Tako-tsubo stress cardiomyopathy is a clinical syndrome marked by transient reduction of left ventricular function in the setting of emotional or physical stress and in the absence of obstructive coronary artery disease. We describe a case of an atypical variant of Tako-tsubo in a male patient following an elective direct current cardioversion (DCCV). Case summary: A 78-year-old male whose atrial fibrillation persisted after earlier unsuccessful direct current DCCV and radiofrequency ablations presented to the emergency department for acutely worsening dyspnoea and orthopnoea 12 h following his most recent DCCV. Previously, he was known to have non-obstructive coronary artery disease. Evaluation was notable for troponin I 0.019 ng/mL (negative <0.050 ng/mL), pro-brain natriuretic peptide 2321 pg/mL (reference range 0.0–900 pg/mL). There were no acute electrocardiogram abnormalities. He required bilevel positive airway pressure but was weaned off eventually to room air. Transthoracic echocardiogram revealed newly reduced left ventricular ejection fraction of 45–50%, associated with hypokinesis of the basal anteroseptal segment, as well as akinesis of mid-inferoseptal and mid-anteroseptal segments. Apical contractility was preserved. On Day 5 of hospitalization, diagnostic left heart catheterization again revealed benign coronary anatomy, and he was discharged home the following day. Discussion: Only five other cases of cardioversion mediated Tako-tsubo cardiomyopathy have been reported in the literature. To our knowledge, this is the first case of DCCV-induced atypical Tako-tsubo cardiomyopathy. Although overall prognosis is favourable, some have been observed to require advanced support therapy. Given risk for life-threatening complications, patients undergoing cardioversion should be educated on symptoms of congestive cardiomyopathy.


  • Open Access

    Facial Diplegia Variant of Guillain-Barré Syndrome in Pregnancy Following COVID-19 Vaccination: A Case Report

    by Adeel S. Zubair, Ju Young Bae, Kunal Desai

    Serious neurologic complications from coronavirus disease 2019 (COVID-19) vaccination are rare, and only a few cases of Guillain-Barré syndrome (GBS) have been reported after COVID-19 vaccination. We present the first reported case of the facial diplegia variant of GBS after recent COVID-19 vaccination in a pregnant woman. The 30-year-old patient was 27 weeks pregnant at the time she was diagnosed with the facial diplegia variant of GBS. Her symptoms began two weeks after she received the Ad26.COV2.S COVID-19 vaccine. A thorough evaluation for GBS was done, including a lumbar puncture that demonstrated elevated cerebrospinal fluid (CSF) protein and nerve conduction study (NCS) that found evidence of a diffuse sensorimotor demyelinating polyneuropathy. Nasal swab testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was negative on two occasions five days apart. All other diagnostic testing was unremarkable or nonexplanatory of the patient’s clinical presentation. She was started on intravenous immunoglobulin (IVIG) and had significantly improved dysphasia, dysarthria, and facial strength. The patient recovered to baseline four weeks after presentation.